Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been discovered to influence this respiratory system of people with DIABETES Mellitus, such as acute respiratory syndrome coronavirus. After predisposing patients to severe COVID 19, a patient with diabetes mellitus already has a weakened immune system. However, preliminary findings suggest that glucose-lowering DPP4 inhibitors have no effect on SARS-COV-2 vulnerability. In sufferer with COVID-19 and s, sodium-glucose co transporter 2 (SGLT2) inhibitors may have a severe effect due to their pharmacological properties.